News & Updates
Showing Oncology articles
Showing
Show Multimedia Only

Pirtobrutinib scores a phase III win in BTKi-pretreated CLL/SLL
14 Jan 2025
byMike Ng
The first phase III trial of pirtobrutinib in haematologic malignancies to readout has demonstrated superiority over investigator's choice in delaying progression in pretreated chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL), with results from the BRUIN CLL-321 study first presented at ASH 2024.
14 Jan 2025

Survival benefit with STRIDE for HCC sustained at 5 years
10 Jan 2025
byAudrey Abella
The updated exploratory analysis of the phase III HIMALAYA trial demonstrates a significant overall survival (OS) benefit at 5 years with the STRIDE* regimen comprising tremelimumab and durvalumab for patients with unresectable hepatocellular carcinoma (HCC).
10 Jan 2025






